CRDAl Stock Overview
Croda International Plc engages in the consumer care, life science, and industrial specialty businesses in in Europe, the Middle East, Africa, North America, Asia, and Latin America.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 3/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 4/6 |
Croda International Plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | UK£47.04 |
52 Week High | UK£70.30 |
52 Week Low | UK£40.18 |
Beta | 0.71 |
1 Month Change | -3.21% |
3 Month Change | -1.16% |
1 Year Change | -32.74% |
3 Year Change | -30.37% |
5 Year Change | -7.72% |
Change since IPO | 99.00% |
Recent News & Updates
Recent updates
Shareholder Returns
CRDAl | GB Chemicals | GB Market | |
---|---|---|---|
7D | -3.7% | -2.7% | 2.8% |
1Y | -32.7% | -37.7% | 1.1% |
Return vs Industry: CRDAl exceeded the UK Chemicals industry which returned -37.5% over the past year.
Return vs Market: CRDAl underperformed the UK Market which returned 0.9% over the past year.
Price Volatility
CRDAl volatility | |
---|---|
CRDAl Average Weekly Movement | 4.3% |
Chemicals Industry Average Movement | 6.9% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.3% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: CRDAl has not had significant price volatility in the past 3 months.
Volatility Over Time: CRDAl's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1925 | 5,852 | Steve Foots | www.croda.com |
Croda International Plc engages in the consumer care, life science, and industrial specialty businesses in in Europe, the Middle East, Africa, North America, Asia, and Latin America. The company offers speciality and active ingredients across beauty care, beauty actives, and home care products, as well as fragrances and flavours. It also provides biologics drug delivery, adjuvant systems, small molecule, protein, and nucleic acid delivery platforms, as well as purity materials for pharmaceutical formulations.
Croda International Plc Fundamentals Summary
CRDAl fundamental statistics | |
---|---|
Market cap | UK£6.57b |
Earnings (TTM) | UK£171.00m |
Revenue (TTM) | UK£1.69b |
38.4x
P/E Ratio3.9x
P/S RatioIs CRDAl overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CRDAl income statement (TTM) | |
---|---|
Revenue | UK£1.69b |
Cost of Revenue | UK£964.50m |
Gross Profit | UK£730.00m |
Other Expenses | UK£559.00m |
Earnings | UK£171.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Jul 30, 2024
Earnings per share (EPS) | 1.22 |
Gross Margin | 43.08% |
Net Profit Margin | 10.09% |
Debt/Equity Ratio | 26.4% |
How did CRDAl perform over the long term?
See historical performance and comparison